A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Failed Treatments with Abiraterone Acetate and Docetaxel.
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Deutenzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Sichuan Haisco Pharmaceutical
Most Recent Events
- 12 Mar 2025 Planned End Date changed from 1 Dec 2024 to 1 Sep 2025.
- 12 Mar 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Sep 2025.
- 04 Dec 2024 Primary endpoint 'Radiographic Progression-Free Survival (rPFS)' is added newly.